Listing mipsagargin in a patent is one thing .. using it in clinical trials and NDA (new drug application) is quite another. However, the fact that MedicNova listed mipsagargin in the patent is itself an indication that other pharma companies are interested in the IP and research of NSPX. If it comes to an FDA approved drug combination of mipsagargin and ibudilast a financial gain for the company would happen.
Market Data 
Markets 
AI
